The Hydration Pharmaceuticals Company Limited (ASX:HPC), which trades as Hydralyte USA, is a small US-focused consumer health Business whose recent disclosures centre on one question: whether lower costs and modest sales growth can stretch a thin cash balance until new funding arrives. The company's own half-year accounts carry an auditor's Going Concern emphasis, which frames the rest of its record.

What the company does

HPC is a wholesale supplier and online retailer of Hydralyte oral hydration products in North America. It sold its non-US Assets to Prestige Consumer Healthcare and now concentrates on mainly E-commerce sales in the United States. Its products are sold partly through distributors Cardinal and Medline.

Latest verified results

For the quarter ended 30 June 2026, the company's Quarterly Report of 31 July 2026 showed net sales of US$695,566, up 13.6 per cent on the March quarter. Net operating cash outflow fell from US$613,000 to US$334,000, and cash at 30 June was US$442,000.

The half-year report lodged on 31 August 2026 showed unaudited Revenue of US$1,203,048, down about 21 per cent from US$1,525,598 a year earlier. HPC attributed this mainly to lower ready-to-drink sales to retailer Publix and temporary stock-outs of two variety packs. The loss after tax narrowed to US$1,057,134 from US$1,438,725. Cash fell from US$1,118,581 at 31 December 2025 to US$442,919, and net assets were US$656,286.

Funding and dilution

RSM, the auditor, drew attention to a material uncertainty about going concern, without modifying its review conclusion. Directors say their forecasts assume a future Capital raise or alternative funding, which is management's assessment rather than a confirmed arrangement.

On 15 June 2026 HPC announced a Placement of 98 million shares at A$0.004 to investor George Karafotios or his nominee, raising A$392,000 before costs, with 49 million Options proposed at A$0.006 subject to Shareholder approval. Board changes accompanied the raise, including a new chair and the departure of chief executive Oliver Baker, who remains as a consultant. Board fees were cut from about A$243,000 to A$120,000 a year, with expected annual cash savings of about A$500,000.

Sector context and risks

Hydration is a crowded consumer category, and HPC relies on a few retail and distribution relationships, so lost shelf space or stock-outs matter; the December 2025 quarter was hurt by a variety pack stock-out. Management's outlook emphasises maintaining sales momentum and a strategic review of capital management and Acquisition prospects, which are statements of intent, not outcomes.

The share register has also changed. The ASX announcement list shows several substantial holder notices in June 2026, a suspension from Quotation on 1 May 2026 with reinstatement on 4 May, and the relodgement of the Annual Report on 1 May. We did not establish the reason for the suspension from the sources read.

Recent announcements and what to watch

The ASX list shows a July and August 2026 trading update on 29 September and results of an extraordinary general meeting on 8 October 2026. We have not been able to read the contents of either document, so readers should consult them directly on the ASX platform.